Cargando…
Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib
Human lives and nations’ economies have been adversely affected worldwide by the COVID-19 pandemic. The hyperinflammatory state associated with the disease may be related to mortality. Systemic glucocorticoid is the first-line therapy for cytokine storm. Various immunomodulatory drugs such as tocili...
Autores principales: | Sharma, Ashish, Ali, Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641367/ https://www.ncbi.nlm.nih.gov/pubmed/34607309 http://dx.doi.org/10.4269/ajtmh.21-0737 |
Ejemplares similares
-
Use of Tofacitinib in the Management of COVID-19 Pneumonia
por: Bande, Balasaheb D
Publicado: (2021) -
Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
por: Shrestha, Gentle Sunder, et al.
Publicado: (2021) -
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021) -
Mesalazine/tofacitinib/vedolizumab: COVID-19 infection: 3 case reports
Publicado: (2021) -
Methotrexate/tofacitinib/tozinameran interaction: COVID-19 pneumonia: case report
Publicado: (2022)